BC3EE2,9B, a synthetic carbazole derivative, upregulates autophagy and synergistically sensitizes human GBM8901 glioblastoma cells to temozolomide.
Glioblastoma multiforme (GBM) is the most fatal form of human brain cancer. Although temozolomide (TMZ), an oral alkylating chemotherapeutic agent, improves the survival rate, the prognosis of patients with GBM remains poor. Naturally occurring carbazole alkaloids isolated from curry leaves (Murraya koenigii Spreng.) have been shown to possess a wide range of anticancer properties. However, the effects of carbazole derivatives on glioblastoma cells remain poorly understood. In the present study, anti‑glioblastoma profiles of a series of synthetic carbazole derivatives were evaluated in vitro. The most promising derivative in this series was BC3EE2,9B, which showed significant anti‑proliferative effects in GBM8401 and GBM8901 cells. BC3EE2,9B also triggered cell‑cycle arrest, most prominently at the G1 stage, and suppressed glioblastoma cell invasion and migration. Furthermore, BC3EE2,9B induced autophagy‑mediated cell death and synergistically sensitized GBM cells to TMZ cytotoxicity. The possible mechanism underlying BC3EE2,9B‑induced autophagy may involve activation of adenosine monophosphate-activated protein kinase and the attenuation of the Akt and mammalian target of the rapamycin downstream signaling pathway. Taken together, the present results provide molecular evidence for the mode of action governing the ability of BC3EE2,9B to sensitize drug‑resistant glioblastoma cells to the chemotherapeutic agent TMZ.
Department and Graduate Institute of Veterinary Medicine and Institute of Veterinary Clinical Science, School of Veterinary Medicine, National Taiwan University, Taipei 10617, Taiwan, R.O.C.
Chien-Min
CM
Chen
Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan, R.O.C.
Jhih-Pu
JP
Syu
Department of Biological Science and Technology, College of Life Sciences, China Medical University, Taichung 404, Taiwan, R.O.C.
Tzong-Der
TD
Way
Graduate Institute of Pharmaceutical Chemistry, College of Pharmacy, China Medical University, Taichung 404, Taiwan, R.O.C.
Li-Jiau
LJ
Huang
Graduate Institute of Pharmaceutical Chemistry, College of Pharmacy, China Medical University, Taichung 404, Taiwan, R.O.C.
Sheng-Chu
SC
Kuo
Department and Graduate Institute of Veterinary Medicine and Institute of Veterinary Clinical Science, School of Veterinary Medicine, National Taiwan University, Taipei 10617, Taiwan, R.O.C.
Chung-Tien
CT
Lin
Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan, R.O.C.
Chih-Li
CL
Lin
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001343:Autophagy / Q000187:drug effects* / Q000235:genetics; D001932:Brain Neoplasms / Q000188:drug therapy / Q000235:genetics; D002227:Carbazoles / Q000494:pharmacology*; D059447:Cell Cycle Checkpoints / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects / Q000235:genetics; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics; D004357:Drug Synergism; D016193:G1 Phase / Q000187:drug effects / Q000235:genetics; D005909:Glioblastoma / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D009361:Neoplasm Invasiveness / Q000235:genetics / Q000473:pathology; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D000077204:Temozolomide; D015854:Up-Regulation / Q000187:drug effects* / Q000235:genetics
D000970:Antineoplastic Agents; D002227:Carbazoles; C041514:carbazole; D003606:Dacarbazine; D051057:Proto-Oncogene Proteins c-akt; D000077204:Temozolomide